Kenneth R. Hande, MD | Authors

IBRAHIM MICHAEL ZAYNEH

2127- 25th St

Ste 206

Articles

Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC

July 02, 2000

In preclinical studies, the topoisomerase I inhibitor irinotecan (Camptosar, CPT-11) has demonstrated activity as a radiosensitizer, probably due to its ability to inhibit potentially lethal radiation damage repair. We conducted a